Literature DB >> 25983856

The Current State of Vaccine Development for Ocular HSV-1 Infection.

D J Royer1, A Cohen2, Djj Carr3.   

Abstract

HSV-1 continues to be the leading cause of infectious corneal blindness. Clinical trials for vaccines against genital HSV infection have been ongoing for more than three decades. Despite this, no approved vaccine exists, and no formal clinical trials have evaluated the impact of HSV vaccines on eye health. We review here the current state of development for an efficacious HSV-1 vaccine and call for involvement of ophthalmologists and vision researchers.

Entities:  

Keywords:  HSV-1; cornea; correlates of protection; immunopathology; vaccine

Year:  2015        PMID： 25983856      PMCID： PMC4431768          DOI： 10.1586/17469899.2015.1004315

Source DB:  PubMed          Journal:  Expert Rev Ophthalmol        ISSN： 1746-9899


  104 in total

1.  Behavioral assessment of visual acuity in mice and rats.

Authors:  G T Prusky; P W West; R M Douglas
Journal:  Vision Res       Date:  2000       Impact factor: 1.886

2.  Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999-2010.

Authors:  Heather Bradley; Lauri E Markowitz; Theda Gibson; Geraldine M McQuillan
Journal:  J Infect Dis       Date:  2013-10-16       Impact factor: 5.226

3.  Efficacy results of a trial of a herpes simplex vaccine.

Authors:  Robert B Belshe; Peter A Leone; David I Bernstein; Anna Wald; Myron J Levin; Jack T Stapleton; Iris Gorfinkel; Rhoda L Ashley Morrow; Marian G Ewell; Abbie Stokes-Riner; Gary Dubin; Thomas C Heineman; Joann M Schulte; Carolyn D Deal
Journal:  N Engl J Med       Date:  2012-01-05       Impact factor: 91.245

Review 4.  Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system.

Authors:  Anthony B Nesburn; Ilham Bettahi; Xiuli Zhang; Xiaoming Zhu; Winston Chamberlain; Rasha E Afifi; Steven L Wechsler; Lbachir BenMohamed
Journal:  Ocul Surf       Date:  2006-10       Impact factor: 5.033

5.  Reversible nerve damage and corneal pathology in murine herpes simplex stromal keratitis.

Authors:  Hongmin Yun; Alexander M Rowe; Kira L Lathrop; Stephen A K Harvey; Robert L Hendricks
Journal:  J Virol       Date:  2014-04-30       Impact factor: 5.103

6.  Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis.

Authors:  Monique van Velzen; David A M C van de Vijver; Freek B van Loenen; Albert D M E Osterhaus; Lies Remeijer; Georges M G M Verjans
Journal:  J Infect Dis       Date:  2013-07-30       Impact factor: 5.226

7.  Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States.

Authors:  Fujie Xu; Maya R Sternberg; Benny J Kottiri; Geraldine M McQuillan; Francis K Lee; Andre J Nahmias; Stuart M Berman; Lauri E Markowitz
Journal:  JAMA       Date:  2006-08-23       Impact factor: 56.272

8.  Correlate of immune protection against HSV-1 genital disease in vaccinated women.

Authors:  Robert B Belshe; Thomas C Heineman; David I Bernstein; Abbie R Bellamy; Marian Ewell; Robbert van der Most; Carolyn D Deal
Journal:  J Infect Dis       Date:  2013-11-27       Impact factor: 5.226

9.  Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody.

Authors:  Adalbert Krawczyk; Michaela A E Arndt; Ludger Grosse-Hovest; Wilko Weichert; Bernd Giebel; Ulf Dittmer; Hartmut Hengel; Dirk Jäger; Karl E Schneweis; Anna M Eis-Hübinger; Michael Roggendorf; Jürgen Krauss
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-08       Impact factor: 11.205

10.  Role of anti-glycoproteins D (anti-gD) and K (anti-gK) IgGs in pathology of herpes stromal keratitis in humans.

Authors:  Kevin R Mott; Yanira Osorio; Ezra Maguen; Anthony B Nesburn; Alec E Wittek; Steve Cai; Subhendra Chattopadhyay; Homayon Ghiasi
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-05       Impact factor: 4.799
View more
  12 in total

1.  Reply to "Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?"

Authors:  Derek J Royer; Daniel J J Carr
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

2.  A STING-dependent innate-sensing pathway mediates resistance to corneal HSV-1 infection via upregulation of the antiviral effector tetherin.

Authors:  D J Royer; D J J Carr
Journal:  Mucosal Immunol       Date:  2015-12-02       Impact factor: 7.313

3.  Impact of Type I Interferon on the Safety and Immunogenicity of an Experimental Live-Attenuated Herpes Simplex Virus 1 Vaccine in Mice.

Authors:  Derek J Royer; Meghan M Carr; Ana J Chucair-Elliott; William P Halford; Daniel J J Carr
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

4.  A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity.

Authors:  Derek J Royer; Hem R Gurung; Jeremy K Jinkins; Joshua J Geltz; Jennifer L Wu; William P Halford; Daniel J J Carr
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

5.  The Neonatal Fc Receptor and Complement Fixation Facilitate Prophylactic Vaccine-Mediated Humoral Protection against Viral Infection in the Ocular Mucosa.

Authors:  Derek J Royer; Meghan M Carr; Hem R Gurung; William P Halford; Daniel J J Carr
Journal:  J Immunol       Date:  2017-07-31       Impact factor: 5.422

6.  Herpesvirus-Associated Lymphadenitis Distorts Fibroblastic Reticular Cell Microarchitecture and Attenuates CD8 T Cell Responses to Neurotropic Infection in Mice Lacking the STING-IFNα/β Defense Pathways.

Authors:  Derek J Royer; Christopher D Conrady; Daniel J J Carr
Journal:  J Immunol       Date:  2016-08-10       Impact factor: 5.422

7.  Herpes Simplex Virus 1 (HSV-1) 0ΔNLS Live-Attenuated Vaccine Protects against Ocular HSV-1 Infection in the Absence of Neutralizing Antibody in HSV-1 gB T Cell Receptor-Specific Transgenic Mice.

Authors:  Grzegorz B Gmyrek; Adrian Filiberti; Micaela Montgomery; Alisha Chitrakar; Derek J Royer; Daniel J J Carr
Journal:  J Virol       Date:  2020-11-23       Impact factor: 5.103

8.  Lack of neonatal Fc receptor does not diminish the efficacy of the HSV-1 0ΔNLS vaccine against ocular HSV-1 challenge.

Authors:  Daniel J J Carr; Amanda N Berube; Adrian Filiberti; Grzegorz B Gmyrek
Journal:  Vaccine       Date:  2021-04-01       Impact factor: 3.641

9.  Noncognate Signals Drive Enhanced Effector CD8+ T Cell Responses through an IFNAR1-Dependent Pathway after Infection with the Prototypic Vaccine, 0ΔNLS, against Herpes Simplex Virus 1.

Authors:  Grzegorz B Gmyrek; Paul Predki; Edward Gershburg; Daniel J J Carr
Journal:  J Virol       Date:  2022-01-19       Impact factor: 6.549

10.  Comparative analysis of the tear protein profile in herpes simplex virus type 1 epithelial keratitis.

Authors:  Hua Yang; Xiaozhao Yang; Yani Wang; Xuan Zheng; Yi Zhang; Yan Shao
Journal:  BMC Ophthalmol       Date:  2020-08-31       Impact factor: 2.209
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.